Diurnal differences in response to oral levodopa
- PMID: 2283524
- PMCID: PMC488274
- DOI: 10.1136/jnnp.53.11.948
Diurnal differences in response to oral levodopa
Abstract
Diurnal differences in duration and quality of motor response to levodopa are frequently described by patients. The quality and duration of motor responses were objectively assessed to morning and afternoon oral levodopa doses in five patients with Parkinsonian motor fluctuations who complained of diurnal variation in response to their normal levodopa medication. Results suggest that under controlled conditions which eliminated the effects of diet and overlapping levodopa effects the response to levodopa remained unchanged throughout the day, and that the duration of response could be predicted by plasma levodopa levels.
Similar articles
-
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.Mov Disord. 1994 Jul;9(4):463-5. doi: 10.1002/mds.870090416. Mov Disord. 1994. PMID: 7969216 Clinical Trial.
-
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.Mov Disord. 1996 Jul;11(4):427-30. doi: 10.1002/mds.870110412. Mov Disord. 1996. PMID: 8813223 Clinical Trial.
-
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.Mov Disord. 1992;7(3):244-8. doi: 10.1002/mds.870070310. Mov Disord. 1992. PMID: 1620142
-
Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.Clin Pharmacokinet. 2017 Sep;56(9):999-1014. doi: 10.1007/s40262-017-0511-y. Clin Pharmacokinet. 2017. PMID: 28236251 Free PMC article. Review.
-
The promise and limitations of controlled-release oral levodopa administration.Clin Neuropharmacol. 1989 Jun;12(3):147-66. doi: 10.1097/00002826-198906000-00001. Clin Neuropharmacol. 1989. PMID: 2663145 Review. No abstract available.
Cited by
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
-
Diurnal effects of motor activity and fatigue in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1993 Aug;56(8):874-7. doi: 10.1136/jnnp.56.8.874. J Neurol Neurosurg Psychiatry. 1993. PMID: 8350103 Free PMC article.
-
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.J Clin Pharmacol. 2013 May;53(5):523-31. doi: 10.1002/jcph.63. Epub 2013 Feb 20. J Clin Pharmacol. 2013. PMID: 23426902 Free PMC article. Clinical Trial.
-
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001. Clin Pharmacokinet. 2006. PMID: 16485914 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical